GIST

In the Chinese population of the global INVICTUS trial, ripretinib was found to have a manageable safety profile and produced a good response rate.

Full results from the phase 3 INVICTUS trial show stable progression-free survival advantage and improved overall survival with ripretinib in patients with an advanced gastrointestinal stromal tumor.

Compared with sunitinib, second-line treatment with ripretinib did not improve progression-free survival in patients with gastrointestinal stromal tumor.

Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.

Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.

A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation

Implications for treating patients with gastrointestinal stromal tumors (GISTs) in the later lines of therapy after switching from 1 treatment to another.

Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss the current treatment options that are available for the treatment of gastrointestinal stromal tumor (GIST).

An overview of mutations in gastrointestinal stromal tumor (GIST) and how they can influence treatment selection.

Considerations for gastrointestinal stromal tumor (GIST) sequencing in the adjuvant setting.

Fadi Braiteh, MD, discusses sequencing in patients with resectable and unresectable gastrointestinal stromal tumors (GISTs) and explains the impact on treatment considerations.

Experts in the field of gastrointestinal stromal tumors (GISTs) discuss the role of sequencing therapy in the frontline and later-line settings.

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

The experts comment on take-home messages, and what they hope to see in the future in treating GIST.

The panel discuss the use of avapritinib in GIST, including doses, toxicities, and secondary resistance to treatment.

Experts discuss KIT and PDGFRα D842V-mutations in GIST and present the NAVIGATOR trial.

Presentation and considerations for a case of PDGFRα D842V-mutated GIST.

A panel of experts review the VOYAGER and INTRIGUE trials.

Key opinion leaders consider later lines of therapy in metastatic KIT exon 9–mutated GIST and how to monitor and mitigate toxicities.

The experts discuss the use of imatinib in patients with KIT exon 9-mutated GIST. Additionally, they comment on surgical options for patients with GIST.

The experts present and discuss a case of a patient with KIT exon 9-mutated GIST, an including an overview of surgical options.

The panelists discuss the phase 3 INVICTUS trial of ripretinib and the phase 1 study of ripretinib intra-patient dose escalation.

Third-line treatment recommendations for patients with GIST and a discussion on side effect management.

Experts discuss the considerations of lines of therapy, comment on molecular testing, and the role of repeat biopsies.

The experts discuss a case presentation of a 66-year-old woman with heavily pretreated GIST, and comment on follow-up times and treatment options.